Project Grant R21AI202159
Award Date 8/18/26
Completion Date 7/31/28
Dollars Obligated $462K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maywood, IL 60153, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded Loyola University of Chicago Health Sciences Campus $158,800 on April 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the anti-inflammatory effects of nucleoside/nucleotide reverse transcriptase inhibitors during bacterial infection. The research examines how bacterial infections trigger induction of endogenous retroviruses and whether inhibiting reverse transcriptase can suppress...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases awarded Northern Illinois University $147,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026. The award funds research investigating how geminivirus viral RNA silencing suppressors (AC2/C2 proteins) subvert the SNRK1/autophagy pathway to suppress host plant antiviral immune responses. The research addresses geminivirus crop disease control by examining defense-counterdefense interactions at...
- The National Institute of Allergy and Infectious Diseases awarded The University of Chicago $451,000 on February 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify novel cellular targets for enhancing targeted RNA degradation in antiviral therapies. The project addresses a critical limitation in ribonuclease-targeting chimeras (RIBOTACs), which degrade viral RNA to prevent replication but achieve only approximately 75% maximum degradation of target...
- The National Institute of Allergy and Infectious Diseases awarded Loyola University of Chicago Health Sciences Campus $223,068 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate affinity maturation mechanisms in ectopic lymphoid tissues formed in allergic lungs. The research will identify molecular features—including activation-induced cytidine deaminase (AID) expression, somatic hypermutation, and clonal selection—that drive affinity...
- The National Institute of Allergy and Infectious Diseases awarded the Scripps Research Institute a Project Grant of $270,443 on June 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to characterize host-specific profiles of defective viral genomes of influenza virus. The research examines defective viral genomes (DVGs) that emerge during influenza virus replication and their role in modulating viral fitness, pathogenicity, and immune responses. The work...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $620,662 on July 2, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research into mechanisms by which quorum-sensing-active Streptococcus pyogenes suppress innate immune responses in macrophages. The research addresses how GAS strains in a quorum-sensing-on state prevent transcription of pro-inflammatory genes despite activation of upstream NF-κB signaling pathways,...
- The National Institute of Allergy and Infectious Diseases awarded $427,626 to The Washington University on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify host factors that mediate nuclear retention of unspliced and partially spliced HIV-1 transcripts. The project will determine mechanisms by which intron-containing HIV-1 RNA molecules remain in the nucleus, contrasting with fully spliced viral messenger RNA that readily accesses host nuclear...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $236,407 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural basis of ARMA-mediated resistance to aminoglycoside antibiotics targeting the bacterial ribosome. The research addresses how ARMA methyltransferases confer high-level resistance to aminoglycosides—a cornerstone class of ribosome-binding antibacterial drugs used...